Acceder

Farmas USA

136K respuestas
Farmas USA
86 suscriptores
Farmas USA
Página
4.304 / 17.033
#34425

Re: Farmas USA

Hoy todo rojo que putos los USA,s2

Worried about the future? Don't be! Put the power of MarketClub on your side for 30 days and only $8.95.
To add more symbols to your Trend Analysis reports, please visit your INO Portfolio. Trend Analysis is a free service powered by MarketClub's Trade Triangle technology.

THRESHOLD PHARMACEUTICALS (NASDAQ:THLD) Very Weak Uptrend
Smart Scan Chart Analysis shows the current uptrend is at a crossroads and has possibly ended. Look for choppy trading action in the nearterm Very Weak Uptrend with very tight stops.
Based on a pre-defined weighted trend formula for chart analysis, THLD scored +60 on a scale from -100 (strong downtrend) to +100 (strong uptrend):


-10 Last Hour Close Below 5 hour Moving Average
+15 New 3 Day High on Monday
+20 Last Price Above 20 Day Moving Average
+25 New 3 Week High, September 18th
-30 New 3 Month Low on August 19

+60 Total Score


Open High Low THLD Price Change
4.770 4.790 4.625 4.650 -0.120

 
ARENA PHARMACEUTICALS (NASDAQ:ARNA) Strong Downtrend
Smart Scan Chart Analysis continues negative longer term. Look for this market to remain weak. Strong Downtrend with money management stops. A triangle indicates the presence of a very strong trend that is being driven by strong forces and insiders.
Based on a pre-defined weighted trend formula for chart analysis, ARNA scored -90 on a scale from -100 (strong downtrend) to +100 (strong uptrend):


+10 Last Hour Close Above 5 Hour Moving Average
-15 New 3 Day Low on Monday
-20 Last Price Below 20 Day Moving Average
-25 New 3 Week Low, August 28th
-30 New 3 Month Low on June 20

-90 Total Score


Open High Low ARNA Price Change
5.820 5.900 5.770 5.870 +0.075

 
NAVIDEA (AMEX:NAVB) Very Weak Downtrend
Smart Scan Chart Analysis shows the current downward trend is at a crossroads and has possibly ended. Look for choppy trading action in the nearterm Very Weak Downtrend with very tight stops.
Based on a pre-defined weighted trend formula for chart analysis, NAVB scored -60 on a scale from -100 (strong downtrend) to +100 (strong uptrend):


+10 Last Hour Close Above 5 Hour Moving Average
-15 New 3 Day Low on Friday
-20 Last Price Below 20 Day Moving Average
-25 New 3 Week Low, August 7th
+30 New 3 Month High on July 2

-60 Total Score


Open High Low NAVB Price Change
2.9000 2.9000 2.8200 2.8701 +0.0401

 
ACHILLION PHARMACEUTICALS (NASDAQ:ACHN) Sidelines Mode
Smart Scan Chart Analysis indicates a counter trend rally is underway The current up-trend could be changing and moving into a trading range Sidelines Mode.
Based on a pre-defined weighted trend formula for chart analysis, ACHN scored +55 on a scale from -100 (strong downtrend) to +100 (strong uptrend):


+10 Last Hour Close Above 5 Hour Moving Average
-15 New 3 Day Low on Wednesday
+20 Last Price Above 20 Day Moving Average
+25 New 3 Week High, September 5th
-30 New 3 Month Low on April 4

+55 Total Score


Open High Low ACHN Price Change
7.3300 7.4199 7.1900 7.4080 +0.1180

 
HORIZON PHARMA (NASDAQ:HZNP) Strong Uptrend
Smart Scan Chart Analysis confirms that a strong uptrend is in place and that the market remains positive longer term. Strong Uptrend with money management stops. A triangle indicates the presence of a very strong trend that is being driven by strong forces and insiders.
Based on a pre-defined weighted trend formula for chart analysis, HZNP scored +100 on a scale from -100 (strong downtrend) to +100 (strong uptrend):


+10 Last Hour Close Above 5 Hour Moving Average
+15 New 3 Day High on Thursday
+20 Last Price Above 20 Day Moving Average
+25 New 3 Week High, August 23rd
+30 New 3 Month High on September 12

+100 Total Score


Open High Low HZNP Price Change
3.160 3.300 3.110 3.240 +0.112

 
AMARIN (NASDAQ:AMRN) Sidelines Mode
Smart Scan Chart Analysis indicates a counter trend rally is underway The current up-trend could be changing and moving into a trading range Sidelines Mode.
Based on a pre-defined weighted trend formula for chart analysis, AMRN scored +55 on a scale from -100 (strong downtrend) to +100 (strong uptrend):


-10 Last Hour Close Below 5 hour Moving Average
-15 New 3 Day Low on Thursday
-20 Last Price Below 20 Day Moving Average
+25 New 3 Week High, August 13th
+30 New 3 Month High on September 5

+55 Total Score


Open High Low AMRN Price Change
6.59 6.66 6.47 6.50 -0.11

 
ZALICUS (NASDAQ:ZLCS) Strong Uptrend
Smart Scan Chart Analysis confirms that a strong uptrend is in place and that the market remains positive longer term. Strong Uptrend with money management stops. A triangle indicates the presence of a very strong trend that is being driven by strong forces and insiders.
Based on a pre-defined weighted trend formula for chart analysis, ZLCS scored +100 on a scale from -100 (strong downtrend) to +100 (strong uptrend):


+10 Last Hour Close Above 5 Hour Moving Average
+15 New 3 Day High on Friday
+20 Last Price Above 20 Day Moving Average
+25 New 3 Week High, August 1st
+30 New 3 Month High on August 2

+100 Total Score


Open High Low ZLCS Price Change
0.7500 0.8150 0.7321 0.7922 +0.0392

 
CATALYST PHARMACEUTICALS (NASDAQ:CPRX) Strong Uptrend
Smart Scan Chart Analysis continues positive longer term. Look for this market to remain firm. Strong Uptrend with money management stops. A triangle indicates the presence of a very strong trend that is being driven by strong forces and insiders.
Based on a pre-defined weighted trend formula for chart analysis, CPRX scored +90 on a scale from -100 (strong downtrend) to +100 (strong uptrend):


-10 Last Hour Close Below 5 hour Moving Average
+15 New 3 Day High on Friday
+20 Last Price Above 20 Day Moving Average
+25 New 3 Week High, August 27th
+30 New 3 Month High on April 19

+90 Total Score


Open High Low CPRX Price Change
2.9200 2.9500 2.8000 2.8702 +0.0102

 
B COMMUNICATIONS (NASDAQ:BCOM) Uptrend
Smart Scan Chart Analysis is showing some near term weakness. However, this market remains in the confines of a longer term Uptrend with tight money management stops.
Based on a pre-defined weighted trend formula for chart analysis, BCOM scored +70 on a scale from -100 (strong downtrend) to +100 (strong uptrend):


-10 Last Hour Close Below 5 hour Moving Average
+15 New 3 Day High on Wednesday
-20 No Data for 20 Day Moving Average
+25 New 3 Week High, September 16th
+30 New 3 Month High on April 9

+70 Total Score


Open High Low BCOM Price Change
18.03 18.28 17.71 17.71 -0.32

 

#34426

Re: Farmas USA

Bueno, este articulo si que ha merecido la pena leerlo. Bajista total, claro esta,pero muy original en cuanto argumentos. No son los tipicos. Menuda parida lo de los impuestos. Y lo del ego y el alma ... ja,ja,ja!!! pero que es esto??

Por los foros, el argumento bajista generalizado se basa en la premisa de que la FDA paralizara ( delay) la decision de ANCHOR hasta que se dispongan de datos del trial de REDUCE-IT, que creo tiene prevista su finalizacion en 2016. Argumento del Bastardo.

Esta claro que no pueden atacar por el lado de las patentes, eso ya lo hicieron en 2011 de forma brutal.
Esta claro que no puede atacar por el lado de los objetivos de rendimiento y efectividad, que son indiscutibles y superaron con creces las exigencias de la FDA. Tampoco contra los efectos secundarios. equivalentes a placebo.
No hay ninguna experiiencia negativa en 10 meses de producto en el mercado.
Los scripts, lentos pero absolutamente estables en tendencia (y lo de lentos para una farma como AMRN habria que verlo, eh?)

La FDA aprobó en 2011 una fase III conducida bajo protocolo SPA tras unas resultados que superaban lo requerido. Han pasado dos años ( DOS AÑOS!!), y no solo no se ha tenido conocimiento por parte de la FDA de ningun cambio de parecer con respecto a sus criterios de evaluacion de ANCHOR sino que ademas la carta de respuesta de los 72 dias fue totalmente limpia. Repito, 2 años y ninguna señal de que lo acordado en el SPA hubiera cambiado en lo mas minimo.

Y aun asi, leo a la peña buscar ese caso excepcional y único en la historia de la FDA que representaria el 0,00001% de los casos evaluados que tras cumplirse todas las exigencias de un SPA y superar sobradamente sus objetivos, el NDA fue denegado.

Ratio risk/reward, joder.

ah, y para llegar a esos 7medios-8 pre-adcom, es decir, posicionarnos por encima de la MM200 ... solo es un +20%. Eso en farmas lo tienes en una semana y te sobran 2 dias.

de vuelta a la playa,ciao

AMRN

Edito:
Le han puesto verde en los comentarios.

#34427

Re: Farmas USA

Framus, ya tenías toda la razón con eso de que hoy era para cerrar o comprar....
De mi cartera, 7 rojas y 2 en verde (aún no está mal por como está el día...)
De mi wathclist de farmas cáncer, 15 rojas y 7 verdes....

Un pequeño desastre....

A ver qué día tenemos enuna de las nuestras un subidón como el de CYCC, que si no, cuesta mucho esfuerzo ir subiendo la cartera de dólar en dólar....

Un saludo y suerte....

#34428

Re: Farmas USA

Yo en VERDE el dia de hoy
.
Estos son los 5 que escogi Brean Murray, 4 en verde y 1 en rojo hoy:

- CTSO +2.04% ningun movimiento en un mes ya
- SNGX +2.06% 2 dias seguidos con gran volume a la alza
- VTUS -2.8% una semana "desinflandose"
- OHRP + 1.91 % despacito ya 30% verde en dos semanas
- IPCI + 4.72 % grandes bloques ayer y hoy de 40,000 a 60,000 acciones cada uno

escogidos en otro lado

INSY -0.78% en INSY estoy arriba 170 %
OMER -5.05% a ver que pasa con este, Wedbush P.O. $28.00, casi 300% de precio actual

#34429

Re: Farmas USA

#34430

Re: Farmas USA

HZNP. quiere estar también en la rampa de lanzamiento. .. volumen y buena subida. .

#34431

Re: Farmas USA

se esta poniendo mas caliente que una perra. Porque no tengo cash sino un perdigonazo si le metia....HZNP

#34432

Re: Farmas USA

Yo la llevo de cuando hizo un suelo en 3,20$, y parecía zona de entrada. Después continuó cayendo, y hice otra entrada en 2,20$.
Ahora mi problema, es cuando soltarlas.
Un saludo

Te puede interesar...
  1. Primeras dudas sobre la 'Trumponomics', ¿corrección o toma de beneficios?
  2. Nvidia bate expectativas pero decepciona. Insiders reafirman su posición